This assumption is based on the available studies conducted in various malignancies 35 and, regarding the resistance to BRAF inhibitors in melanoma, based on the observation that resistant cell lines tend to have a slower doubling times compared with sensitive cell lines 35. The gene discussed is BRAF; the disease is melanoma.